Killebrew Larry K, Oneson Ruth H
Oklahoma Breast Care Center, Oklahoma City, Oklahoma 73120, USA.
Breast J. 2006 Jul-Aug;12(4):302-8. doi: 10.1111/j.1075-122X.2006.00268.x.
The objective of this research was to determine whether biopsy of the breast using a percutaneous intact specimen sampling device influences the underestimation rate of ductal carcinoma in situ (DCIS) compared to a vacuum-assisted core needle biopsy (VACNB) device. This study was a retrospective comparison of two series of 800 consecutive patients that underwent stereotactic biopsy of the breast for mammographic lesions presenting as microcalcifications classified by our institution as Breast Imaging Reporting and Data System (BI-RADS) 4 or 5. In the first series of patients (n = 800), a VACNB device was used; in the second series (n = 800), a vacuum-assisted percutaneous intact specimen biopsy (VAPIB) device was used. Initial diagnoses were made from the histopathologic examination of the tissue retrieved at biopsy. Lesions presenting as DCIS or atypical ductal hyperplasia (ADH) after percutaneous biopsy were then compared to the histopathologic analysis of specimens retrieved at surgical biopsy. DCIS upgrades were defined as cases in which the diagnosis of the stereotactic biopsy was DCIS and the diagnosis of the subsequent surgical excision was infiltrating ductal carcinoma (IDC). ADH upgrades were defined as cases in which the diagnosis of the stereotactic biopsy specimen was ADH and the diagnosis of the surgical excision was DCIS, lobular carcinoma in situ (LCIS), or IDC. The lesions retrieved by both biopsy techniques yielded a similar pathology distribution. Underestimation of DCIS occurred less frequently (p = 0.06) in the biopsy samples taken using the intact biopsy device (1/31, 3.2%) as compared to biopsy samples taken using the core needle biopsy device (7/36, 19.4%). No significant adverse events were reported. Breast biopsy can be performed safely and accurately using a vacuum-assisted percutaneous intact specimen sampling device. In this study, such a device trended toward fewer underestimations of DCIS at biopsy compared to the vacuum-assisted core needle sampling biopsy method.
本研究的目的是确定与真空辅助芯针活检(VACNB)设备相比,使用经皮完整样本采样设备进行乳腺活检是否会影响导管原位癌(DCIS)的低估率。本研究是对两组各800例连续患者的回顾性比较,这些患者因乳腺钼靶检查发现微钙化病变而接受乳腺立体定向活检,这些病变被本机构分类为乳腺影像报告和数据系统(BI-RADS)4或5级。在第一组患者(n = 800)中,使用VACNB设备;在第二组(n = 800)中,使用真空辅助经皮完整样本活检(VAPIB)设备。初始诊断基于活检获取组织的组织病理学检查。然后将经皮活检后表现为DCIS或非典型导管增生(ADH)的病变与手术活检获取标本的组织病理学分析结果进行比较。DCIS升级定义为立体定向活检诊断为DCIS而后续手术切除诊断为浸润性导管癌(IDC)的病例。ADH升级定义为立体定向活检标本诊断为ADH而手术切除诊断为DCIS、小叶原位癌(LCIS)或IDC的病例。两种活检技术获取的病变病理分布相似。与使用芯针活检设备获取的活检样本(7/36,19.4%)相比,使用完整活检设备获取的活检样本中DCIS低估情况发生频率较低(p = 0.06)(1/31,3.2%)。未报告显著不良事件。使用真空辅助经皮完整样本采样设备可安全、准确地进行乳腺活检。在本研究中,与真空辅助芯针采样活检方法相比,这种设备在活检时对DCIS的低估倾向较少。